New Journal Website is available at:

Published by: Kowsar

Oral Iron Therapy with Polysaccharide-Iron Complex May be Useful in Increasing the Ferritin Level for a Short Time in Patients with Dilated Cardiomyopathy

Sepideh Taghavi 1 , Afsaneh Amiri 1 , Ahmad Amin 1 , Amirreza Ehsani 1 , Majid Maleki 1 and Nasim Naderi 1 , *
Authors Information
1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Research in Cardiovascular Medicine: January 2017, 6 (1); e39816
  • Published Online: August 8, 2016
  • Article Type: Research Article
  • Received: June 7, 2016
  • Revised: July 3, 2016
  • Accepted: July 22, 2016
  • DOI: 10.5812/cardiovascmed.39816

To Cite: Taghavi S, Amiri A, Amin A, Ehsani A, Maleki M, et al. Oral Iron Therapy with Polysaccharide-Iron Complex May be Useful in Increasing the Ferritin Level for a Short Time in Patients with Dilated Cardiomyopathy, Res Cardiovasc Med. 2017 ;6(1):e39816. doi: 10.5812/cardiovascmed.39816.

Copyright: Copyright © 2017, Research in Cardiovascular Medicine. .
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8): 803-69[DOI][PubMed]
  • 2. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361(25): 2436-48[DOI][PubMed]
  • 3. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012; 14(4): 423-9[DOI][PubMed]
  • 4. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010; 31(15): 1872-80[DOI][PubMed]
  • 5. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015; 17(3): 248-62[DOI][PubMed]
  • 6. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008; 51(2): 103-12[DOI][PubMed]
  • 7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J. 2015; 36(11): 657-68[DOI][PubMed]
  • 8. Gutzwiller FS, Pfeil AM, Comin-Colet J, Ponikowski P, Filippatos G, Mori C, et al. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. Int J Cardiol. 2013; 168(4): 3878-83[DOI][PubMed]
  • 9. Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013; 29(4): 291-303[DOI][PubMed]
  • 10. Fei. C. . Iron Deficiency Anemia 215;
  • 11. McDiarmid T, Johnson ED. Clinical inquiries. Are any oral iron formulations better tolerated than ferrous sulfate? J Fam Pract. 2002; 51(6): 576[PubMed]
  • 12. Naude S, Clijsen S, Naulaers G, Daniels H, Vanhole C, Devlieger H. Iron supplementation in preterm infants: a study comparing the effect and tolerance of a Fe2+ and a nonionic FeIII compound. J Clin Pharmacol. 2000; 40(12 Pt 2): 1447-51[PubMed]
  • 13. Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1: 7857[DOI][PubMed]
  • 14. Bereman RD, Berg KA. The structure, size and solution chemistry of a polysaccharide iron complex (Niferex). Inorganica Chimica Acta. 1989; 155(2): 183-9
  • 15. Coe EM, Bowen LH, Speer JA, Wang Z, Sayers DE, Bereman RD. The recharacterization of a polysaccharide iron complex (Niferex). J Inorg Biochem. 1995; 58(4): 269-78[PubMed]
  • 16. Johnson C, Rosowski E, Zimmerman S. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN. Advances in peritoneal dialysis Conference on Peritoneal Dialysis. 1991;
  • 17. Johnson DW. Intravenous versus oral iron supplementation in peritoneal dialysis patients. Perit Dial Int. 2007; 27 Suppl 2: 255-60[PubMed]
  • 18. Liu TC, Lin SF, Chang CS, Yang WC, Chen TP. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study. Int J Hematol. 2004; 80(5): 416-20
  • 19. Piccinni L, Ricciotti M. Therapeutic effectiveness of an iron-polysaccharide complex in comparison with iron fumarate in the treatment of iron deficiency anaemias. Panminerva Med. 1982; 24(3): 213-20[PubMed]
  • 20. Yao L, Fan Q,, Bo XL. Observation on the curative effect of polysaccharide iron complex (Niferex) to treat patients with iron deficiency anemia. J Xinjiang Med Uni. 2009; 11: 16
  • 21. Zhang ZS, Wang XM, Han ZP, Yin L, Zhao MX, Yu SC. Physicochemical properties and inhibition effect on iron deficiency anemia of a novel polysaccharide-iron complex (LPPC). Bioorg Med Chem Lett. 2012; 22(1): 489-92[DOI][PubMed]
  • 22. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW. The 6-minutewalk: a new measure of exercise capacity in patients with chronic heart failure. Canadian Med Asso J. 1985; 132(8): 919
  • 23. Bayraktar UD, Bayraktar S. Treatment of iron deficiency anemia associated with gastrointestinal tract diseases. World J Gastroenterol. 2010; 16(22): 2720-5[PubMed]
  • 24. Feagan BG, Wong CJ, Kirkley A, Johnston DW, Smith FC, Whitsitt P, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med. 2000; 133(11): 845-54[PubMed]
  • 25. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther. 2001; 23(10): 1637-71[PubMed]
  • 26. Mohie-Eldin MY, Frankel RB, Gunther L. A comparison of the magnetic properties of polysaccharide iron complex (PIC) and ferritin. J Magnetism Magnetic Material. 1994; 135(1): 65-81
  • 27. Sanders JF. Clinical response to iron-polysaccharide complex in geriatric patients with iron-deficiency anemia. Mich Med. 1968; 67(11): 726-7[PubMed]
  • 28. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995; 25(3): 433-9[PubMed]
  • 29. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998; 339(9): 578-83[DOI][PubMed]
  • 30. McCluskey SA, Karkouti K, Ghannam M. Treatment of Post Operative Anemia: Intravenous Iron Compared to Intravenous Iron and Erythropoietin. Anesthesiol. 2005; 103(454)
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader